Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition and agribusiness sector fund.
| Company | Date | Round | Size | Participants |
| Altheos | 2/12 | Series A | $12.5M | 3 |
| Aviir | 12/11 | Series E | $10M | 4 |
| Dermira | 10/11 | Series A | $42M | 3 |
| Nevro | 7/11 | Unattributed | $58M | 7 |
| Conatus Pharmaceuticals | 2/11 | Series B | $20M | 6 |
| NextWave Pharmaceuticals | 1/11 | Series C | $45M | 7 |
| IDEV Technologies | 10/10 | Series D | $46M | 5 |
| Altheos | 4/10 | Series A | $20M | 5 |
| Merus | 1/10 | Series B | €21.7M | 4 |
| Aviir | 1/10 | Debt | $4.2M | 3 |
| Metabolex | 11/09 | Unattributed | $8.6M | 12 |
| Calypso Medical | 11/09 | Series E | $50M | 4 |
| Epizyme | 10/09 | Series B | $32M | 5 |
| Sunesis Pharmaceuticals | 4/09 | Unattributed | $43.5M | 9 |
| VIA Pharmaceuticals | 3/09 | Debt | $10M | 1 |
| BrainCells | 3/08 | Series B | $30M | 6 |
| Aragon Surgical | 1/08 | Series B | $25M | 4 |
| Aviir | 10/07 | Series B | $11.3M | 3 |
| Presidio Pharmaceuticals | 8/07 | Series B | $26M | 5 |
| Vivaldi Biosciences | 5/07 | Series A | $2M | 1 |
| Metabolex | 4/07 | Series D | $32M | 16 |
| MAP Pharmaceuticals | 3/07 | Series D | $50M | 6 |
| Phenomix | 3/07 | Series C | $55M | 10 |
| PTC Therapeutics | 11/05 | Unattributed | $26.6M | 9 |
| Epocrates | 8/02 | Series C | 5 | |
| Epocrates | 8/00 | Series B | $35M | 5 |
